239 related articles for article (PubMed ID: 16132084)
1. Controlled intracellular localization and enhanced antisense effect of oligonucleotides by chemical conjugation.
Kubo T; Zhelev Z; Bakalova R; Ohba H; Doi K; Fujii M
Org Biomol Chem; 2005 Sep; 3(18):3257-9. PubMed ID: 16132084
[TBL] [Abstract][Full Text] [Related]
2. Antisense inhibition of human telomerase by phosphorothioate oligonucleotide-peptide conjugates.
Diala I; Murao S; Fujii M
Nucleic Acids Symp Ser (Oxf); 2008; (52):679-80. PubMed ID: 18776562
[TBL] [Abstract][Full Text] [Related]
3. Highly sensitive inhibition of hTERT mRNA expression and telomerase activity by DNA-signal-peptide conjugates.
Kubo T; Bakalova R; Zhelev Z; Ohba H; Fujii M
Nucleic Acids Symp Ser (Oxf); 2005; (49):337-8. PubMed ID: 17150771
[TBL] [Abstract][Full Text] [Related]
4. Precisely controlled intracellular delivery of DNA-peptide conjugates.
Kubo T; Kanno K; Rumiana B; Ohba H; Fujii M
Nucleic Acids Symp Ser (Oxf); 2004; (48):99-100. PubMed ID: 17150497
[TBL] [Abstract][Full Text] [Related]
5. Antisense effects of DNA-peptide conjugates.
Kubo T; Bakalova R; Ohba H; Fujii M
Nucleic Acids Res Suppl; 2003; (3):179-80. PubMed ID: 14510439
[TBL] [Abstract][Full Text] [Related]
6. Control of intracellular delivery of oligonucleotides by signal peptides and genetic expression in human cells.
Kubo T; Kanno K; Ohba H; Rumiana B; Fujii M
Nucleic Acids Symp Ser (Oxf); 2004; (48):303-4. PubMed ID: 17150599
[TBL] [Abstract][Full Text] [Related]
7. Enhanced cellular uptake and cytotoxicity studies of organometallic bioconjugates of the NLS peptide in Hep G2 cells.
Noor F; Kinscherf R; Bonaterra GA; Walczak S; Wölfl S; Metzler-Nolte N
Chembiochem; 2009 Feb; 10(3):493-502. PubMed ID: 19115329
[TBL] [Abstract][Full Text] [Related]
8. Synthesis of phosphorothioate oligonucleotide-peptide conjugates by solid phase fragment condensation.
Diala I; Osada A; Maruoka S; Imanisi T; Murao S; Ato T; Ohba H; Fujii M
Bioorg Med Chem Lett; 2007 Dec; 17(23):6576-8. PubMed ID: 17942304
[TBL] [Abstract][Full Text] [Related]
9. [Antisense oligonucleotides with antitumor activity].
Otvös L; Sági G
Magy Onkol; 2004; 48(3):221-7. PubMed ID: 15520872
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of human telomerase by oligonucleotide chimeras, composed of an antisense moiety and a chemically modified homo-oligonucleotide.
Tarkanyi I; Horváth A; Szatmari I; Eizert H; Vámosi G; Damjanovich S; Ségal-Bendirdjian E; Aradi J
FEBS Lett; 2005 Feb; 579(6):1411-6. PubMed ID: 15733850
[TBL] [Abstract][Full Text] [Related]
11. A novel anionic dendrimer for improved cellular delivery of antisense oligonucleotides.
Hussain M; Shchepinov M; Sohail M; Benter IF; Hollins AJ; Southern EM; Akhtar S
J Control Release; 2004 Sep; 99(1):139-55. PubMed ID: 15342187
[TBL] [Abstract][Full Text] [Related]
12. Cellular uptake of antisense morpholino oligomers conjugated to arginine-rich peptides.
Moulton HM; Nelson MH; Hatlevig SA; Reddy MT; Iversen PL
Bioconjug Chem; 2004; 15(2):290-9. PubMed ID: 15025524
[TBL] [Abstract][Full Text] [Related]
13. Stability of cell-penetrating peptide-morpholino oligomer conjugates in human serum and in cells.
Youngblood DS; Hatlevig SA; Hassinger JN; Iversen PL; Moulton HM
Bioconjug Chem; 2007; 18(1):50-60. PubMed ID: 17226957
[TBL] [Abstract][Full Text] [Related]
14. Improved cellular uptake of antisense peptide nucleic acids by conjugation to a cell-penetrating peptide and a lipid domain.
Shiraishi T; Nielsen PE
Methods Mol Biol; 2011; 751():209-21. PubMed ID: 21674333
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of cell-penetrating peptides (CPPs) as vehicles for intracellular delivery of antisense peptide nucleic acid (PNA).
Bendifallah N; Rasmussen FW; Zachar V; Ebbesen P; Nielsen PE; Koppelhus U
Bioconjug Chem; 2006; 17(3):750-8. PubMed ID: 16704214
[TBL] [Abstract][Full Text] [Related]
16. Design of carrier peptide-oligonucleotide conjugates with rapid membrane translocation and nuclear localization properties.
Chaloin L; Vidal P; Lory P; Méry J; Lautredou N; Divita G; Heitz F
Biochem Biophys Res Commun; 1998 Feb; 243(2):601-8. PubMed ID: 9480855
[TBL] [Abstract][Full Text] [Related]
17. Transcription inhibition of oncogenic KRAS by a mutation-selective peptide nucleic acid conjugated to the PKKKRKV nuclear localization signal peptide.
Cogoi S; Codognotto A; Rapozzi V; Meeuwenoord N; van der Marel G; Xodo LE
Biochemistry; 2005 Aug; 44(31):10510-9. PubMed ID: 16060660
[TBL] [Abstract][Full Text] [Related]
18. Improved cellular activity of antisense peptide nucleic acids by conjugation to a cationic peptide-lipid (CatLip) domain.
Koppelhus U; Shiraishi T; Zachar V; Pankratova S; Nielsen PE
Bioconjug Chem; 2008 Aug; 19(8):1526-34. PubMed ID: 18646838
[TBL] [Abstract][Full Text] [Related]
19. Nuclear localization and antisense effect of PNA internalized by ASGP-R-mediated endocytosis with protein/DNA conjugates.
Ishihara T; Kano A; Obara K; Saito M; Chen X; Park TG; Akaike T; Maruyama A
J Control Release; 2011 Oct; 155(1):34-9. PubMed ID: 20955741
[TBL] [Abstract][Full Text] [Related]
20. Factors determining the efficacy of nuclear delivery of antisense oligonucleotides by gold nanoparticles.
Liu Y; Franzen S
Bioconjug Chem; 2008 May; 19(5):1009-16. PubMed ID: 18393455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
